IN THE CLAIMS

Please cancel claims 2, 5, 6, 12, 14, 31, 32, 35, 36 and 38, without prejudice to Applicants' right to pursue the subject matter of these claims in another application, and amend claims 1, 7, 16, 26, 27, 37, 39 and 43, as follows:

1. (CURRENTLY AMENDED) A pharmaceutical composition comprising an isolated herpes simplex virus (HSV) polypeptide, wherein the polypeptide ~~comprises a U_L19, U_L21, or~~ consists of amino acids 105-126, 125-146, 187-206, 105-190 or 177-220 of U_L49 protein, and a pharmaceutically acceptable carrier.

2. (CANCELED)

3. (PREVIOUSLY PRESENTED) The composition of claim 1, wherein the polypeptide is a fusion protein.

4. (PREVIOUSLY PRESENTED) The composition of claim 3, wherein the fusion protein is soluble.

5. (CANCELED)

6. (CANCELED)

7. (CURRENTLY AMENDED) A polynucleotide that encodes a polypeptide ~~comprising an amino acid sequence~~ consisting essentially of:

~~(a) amino acids 1078-1319 of U_L19;~~

~~(b) amino acids 148-181 of U_L21;~~

~~(c)~~ amino acids 105-126, 125-146, 187-206, 105-190 or 177-220 of U_L49;

~~(d) amino acids 1-273 of glycoprotein E (gE); or~~

~~(e) amino acids 185-197 or 209-221 of VP16~~.

8. (PREVIOUSLY PRESENTED) A vector comprising the polynucleotide of claim 7.

9. (PREVIOUSLY PRESENTED) A host cell transformed with the vector of claim 8.

10. (PREVIOUSLY PRESENTED) A method of producing an HSV polypeptide comprising culturing the host cell of claim 9 and recovering the polypeptide so produced.

11. (PREVIOUSLY PRESENTED) An HSV polypeptide produced by the method of claim 10.

12. (CANCELED)

13. (PREVIOUSLY PRESENTED) A pharmaceutical composition comprising the polynucleotide of claim 7 and a pharmaceutically acceptable carrier.

14. (CANCELED)

15. (PREVIOUSLY PRESENTED) A recombinant virus genetically modified to express the polypeptide of claim 11.

16. (CURRENTLY AMENDED) The recombinant virus of claim ~~14~~ 15 which is a vaccinia virus, canary pox virus, lentivirus, retrovirus, herpes virus or adenovirus.

17. (PREVIOUSLY PRESENTED) A pharmaceutical composition comprising the virus of claim 16 and a pharmaceutically acceptable carrier.

18.-25. (CANCELED)

26. (CURRENTLY AMENDED) A method of treating ~~or preventing~~ an HSV infection in a subject comprising administering the composition of claim 1 to the subject.

27. (CURRENTLY AMENDED) A method of treating ~~or preventing~~ an HSV infection in a subject comprising administering the pharmaceutical composition of claim ~~2~~ 13 to the subject.

28.-29. (CANCELED)

30. (PREVIOUSLY PRESENTED) The pharmaceutical composition of claim 1, further comprising an adjuvant.

31. (CANCELED)

32. (CANCELED)

33. (PREVIOUSLY PRESENTED) The pharmaceutical composition of claim 13, further comprising an adjuvant.

34. (PREVIOUSLY PRESENTED) The pharmaceutical composition of claim 17, further comprising an adjuvant.

35. (CANCELED)

36. (CANCELED)

37. (CURRENTLY AMENDED) A method of enhancing the production of HSV-specific antibodies in a subject comprising administering to the subject an isolated polypeptide that ~~comprises an immunogenic fragment of U_L19, U_L21, U_L49, glycoprotein E (gE) or VP16~~ consists of amino acids 105-126, 125-146, 187-206, 105-190 or 177-220 of U_L49.

38. (CANCELED)

39. (CURRENTLY AMENDED) A recombinant non-HSV virus genetically modified to express a polypeptide that consists of amino acids 105-126, 125-146, 187-206, 105-190 or 177-220 of ~~U_L19, U_L21, or~~ U_L49 protein.

40. (PREVIOUSLY PRESENTED) The recombinant non-HSV virus of claim 39 which is a vaccinia virus, canary pox virus, lentivirus, retrovirus, herpes virus or adenovirus.

41. (PREVIOUSLY PRESENTED) A pharmaceutical composition comprising the non-HSV virus of claim 39 and a pharmaceutically acceptable carrier, wherein the virus is a vaccinia virus or a canary pox virus.

42. (PREVIOUSLY PRESENTED) The pharmaceutical composition of claim 41, further comprising an adjuvant.

43. (CURRENTLY AMENDED) A fusion protein comprising an HSV polypeptide fused to a heterologous polypeptide, wherein the HSV polypeptide consists essentially of amino acids ~~1078-1319 of U_L19, 148-181 of U_L21;~~ 105-126, 125-146, 187-206, 105-190 or 177-220 of U_L49~~, 1-273 of glycoprotein E (gE); or 185-197 or 209-221 of VP16~~.

44. (PREVIOUSLY PRESENTED) A fusion protein of claim 43 that is soluble.

45. (PREVIOUSLY PRESENTED) A polynucleotide that encodes a fusion protein of claim 43.

46. (PREVIOUSLY PRESENTED) A vector comprising the polynucleotide of claim 45.

47. (PREVIOUSLY PRESENTED) A host cell transformed with the vector of claim 46.

48. (PREVIOUSLY PRESENTED) A method of producing a fusion protein comprising culturing the host cell of claim 47 and recovering the fusion protein so produced.

49. (PREVIOUSLY PRESENTED) A fusion protein produced by the method of claim 48.

50. (PREVIOUSLY PRESENTED) A fusion protein of claim 49 that is soluble.

51. (PREVIOUSLY PRESENTED) A pharmaceutical composition comprising the fusion protein of claim 43, and a pharmaceutically acceptable carrier.

52. (PREVIOUSLY PRESENTED) The pharmaceutical composition of claim 51, further comprising an adjuvant.

53. (PREVIOUSLY PRESENTED) A pharmaceutical composition comprising the fusion protein of claim 49, and a pharmaceutically acceptable carrier.

54. (PREVIOUSLY PRESENTED) The pharmaceutical composition of claim 53, further comprising an adjuvant.